Press Releases & News

LA JOLLA, CALIF (September 8, 2022)-- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced that senior management will present a company overview at two upcoming investor conferences: SALT New York 2022 on Monday,…

LA JOLLA, CALIF--August 2, 2022--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, is pleased to announce that City of Hope has received U.S. Food and Drug Administration (FDA) authorization to proceed with a…

LA JOLLA, Calif. – June 28, 2022 – Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, today announced the appointment of W.K. Alfred Yung, M.D., Professor, Neuro-Oncology at the MD Anderson Cancer Center, to…

LA JOLLA, Calif., — Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, today announced that Stephen Thesing, Chief Business Officer, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at…

LA JOLLA, Calif., — Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, has been granted a new patent (No. US 11,285,194, Combination immunotherapy approach for treatment of cancer) by the U.S. Patent and Trademark Office (USPTO)…

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a Nevada corporation (“Calidi”), is a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, announced today the appointment of Alfonso "Chito" Zulueta to its Board of Directors, effective February 7, 2022. Zulueta…

-Total gross proceeds from transaction expected to be approximately $117 million prior to redemptions, combining $25 million PIPE and up to $92 million held in Edoc trust account- -Anticipated cash resources will fund Calidi’s NeuroNova and SuperNova development programs through multiple clinical milestones- -Business combination…

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today that its physician advisor, Maciej S. Lesniak, MD, Department Chair of Neurological Surgery, Feinberg School of Medicine, Northwestern University, will present at the…

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its selection as a finalist for presentation during the Innovation Showcase at the upcoming annual Oncolytic Virotherapy Summit, which will be held October…

LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company with novel allogeneic stem cell platforms for delivery of oncolytic viruses, together with the University of Chicago and City of Hope, a world renowned NCI-Designated Comprehensive Cancer Center, based in Duarte, California, have entered into…